AIM:To study the antitumour activity of resveratrol andits effect on the expression of cell cycle proteins includingcyclin D1,cyclin B1 and p34cdc2 in transplanted liver cancerof murine.METHODS:Murine transplanted hepatoma H22 model wasused to evaluate the in vivo antitumor activity of resveratrol.Following abdominal administration of resveratrol,thechange in tumour size was recorded and the proteinexpression of cyclin D1,cyclin B1 and p34cdc2 in the tumorand adjacent noncancerous liver tissues were measuredby immunohistochemistry.RESULTS:Following treatment of H22 tumour bearing micewith resveratrol at 10 or 15 mg/kg bodyweight for 10 days,the growth of murine transplantable liver cancer was inhibitedby 36.3% or 49.3%,respectively.The inhibitory effectwas significant compared to that in control group (P<0.05).The level of expression of cyclin B1 and p34cdc2 proteinwas decreased in the transplantable murine hepatoma 22treated with resveratrol whereas the expression of cyclinD1 protein did not change.CONCLUSION:Resveratrol exhibits anti-tumour activitieson murine hepatoma H22.The underlying anti-tumourmechanism of resveratrol might involve the inhibition of thecell cycle progression by decreasing the expression ofcyclinB1 and p34cdc2 protein. AIM: To study the antitumor activity of resveratrol andits effect on the expression of cell cycle proteins including cyclin D1, cyclin B1 and p34cdc2 in transplanted liver cancer of murine. METHODS: Murine transplanted hepatoma H22 model was used to evaluate the in vivo antitumor activity of resveratrol. abdominal administration of resveratrol, the change in tumor size was was and the proteinexpression of cyclin D1, cyclin B1 and p34cdc2 in the tumorand adjacent noncancerous liver tissues were measured by immunohistochemistry .RESULTS: Following treatment of H22 tumor bearing mice with resveratrol at 10 or 15 mg / kg Bodyweight for 10 days, the growth of murine transplantable liver cancer was inhibited by 36.3% or 49.3%, respectively. The inhibitory effect was significant compared to that in control group (P <0.05). The level of expression of cyclin B1 and p34cdc2 protein was decreased in the transplantable murine hepatoma 22treated with resveratrol whereas the expression of cyclinD1 protein did not change. CONCLUSION: Resveratrol exhibits anti-tumor activities of murine hepatoma H22. The underlying anti-tumor mechanism of resveratrol might involve the inhibition of the cell cycle progression by decreasing the expression of cyclinB1 and p34cdc2 protein.